MVCD4
MCID: MCR133
MIFTS: 41

Microvascular Complications of Diabetes 4 (MVCD4)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 4

MalaCards integrated aliases for Microvascular Complications of Diabetes 4:

Name: Microvascular Complications of Diabetes 4 56 73 29 13 6 39
Diabetic Nephropathy 73 71
Mvcd4 56 73
Microvascular Complications of Diabetes, Susceptibility to, 4 56
Nephropathy, Diabetic, Susceptibility to 56
Nephropathy, Diabetic 56

Classifications:



External Ids:

OMIM 56 612628
OMIM Phenotypic Series 56 PS603933
MeSH 43 D048909
UMLS 71 C0011881

Summaries for Microvascular Complications of Diabetes 4

UniProtKB/Swiss-Prot : 73 Microvascular complications of diabetes 4: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 4, also known as diabetic nephropathy, is related to atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease and microvascular complications of diabetes 3. An important gene associated with Microvascular Complications of Diabetes 4 is IL1RN (Interleukin 1 Receptor Antagonist). The drugs Pioglitazone and Zaleplon have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and pancreas.

More information from OMIM: 612628 PS603933

Related Diseases for Microvascular Complications of Diabetes 4

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 4 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 421)
# Related Disease Score Top Affiliating Genes
1 atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease 12.3
2 microvascular complications of diabetes 3 12.1
3 microvascular complications of diabetes 7 12.0
4 microvascular complications of diabetes 6 11.9
5 microvascular complications of diabetes 5 11.6
6 diabetic angiopathy 11.6
7 microvascular complications of diabetes 1 11.4
8 microvascular complications of diabetes 2 11.4
9 fibrosis of extraocular muscles, congenital, 1 10.6
10 end stage renal failure 10.6
11 hypertension, essential 10.5
12 kidney hypertrophy 10.4
13 pre-eclampsia 10.4
14 atherosclerosis susceptibility 10.3
15 hypercholesterolemia, familial, 1 10.3
16 nephrosclerosis 10.3
17 hyperuricemia 10.3
18 diabetic neuropathy 10.3
19 hypoglycemia 10.3
20 cytokine deficiency 10.3
21 proteasome-associated autoinflammatory syndrome 1 10.3
22 kidney disease 10.3
23 congestive heart failure 10.3
24 diabetes mellitus 10.3
25 yemenite deaf-blind hypopigmentation syndrome 10.3
26 muscle hypertrophy 10.3
27 glucose intolerance 10.3
28 arteries, anomalies of 10.3
29 hypertriglyceridemia, familial 10.3
30 hyperlipoproteinemia, type iii 10.3
31 coronary artery anomaly 10.3
32 cerebrovascular disease 10.3
33 wilms tumor 5 10.3
34 focal segmental glomerulosclerosis 10.3
35 hyperglycemia 10.3
36 systemic lupus erythematosus 10.2
37 homocysteinemia 10.2
38 rapidly involuting congenital hemangioma 10.2
39 creatinine clearance quantitative trait locus 10.2
40 deficiency anemia 10.2
41 lipoid nephrosis 10.2
42 cardiovascular system disease 10.2
43 chronic kidney disease 10.2
44 arterial calcification, generalized, of infancy, 1 10.2
45 coronary heart disease 1 10.2
46 eclampsia 10.2
47 b-cell lymphoma 10.2
48 fatty liver disease 10.2
49 autoimmune disease 10.2
50 wilms tumor 1 10.2

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 4:



Diseases related to Microvascular Complications of Diabetes 4

Symptoms & Phenotypes for Microvascular Complications of Diabetes 4

Clinical features from OMIM:

612628

Drugs & Therapeutics for Microvascular Complications of Diabetes 4

Drugs for Microvascular Complications of Diabetes 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 341)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
3
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
4
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
5
Atenolol Approved Phase 4 29122-68-7 2249
6
Methyldopa Approved Phase 4 555-30-6 38853
7
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
8
Clonidine Approved Phase 4 4205-90-7 2803
9
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
10
Capsaicin Approved Phase 4 404-86-4 1548943
11
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
12
Probucol Approved, Investigational Phase 4 23288-49-5 4912
13
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
14
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
15
Ramipril Approved Phase 4 87333-19-5 5362129
16
Zinc Approved, Investigational Phase 4 7440-66-6 32051
17
Doxazosin Approved Phase 4 74191-85-8 3157
18
Atorvastatin Approved Phase 4 134523-00-5 60823
19
Indapamide Approved Phase 4 26807-65-8 3702
20
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
21
Trandolapril Approved Phase 4 87679-37-6 5484727
22
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
23
Nisoldipine Approved Phase 4 63675-72-9 4499
24
Insulin glargine Approved Phase 4 160337-95-1
25
Insulin glulisine Approved Phase 4 207748-29-6
26
Liraglutide Approved Phase 4 204656-20-2 44147092
27
Nitric Oxide Approved Phase 4 10102-43-9 145068
28
Allopurinol Approved Phase 4 315-30-0 2094
29
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
30
Insulin lispro Approved Phase 4 133107-64-9
31
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
32
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
33
Glimepiride Approved Phase 4 93479-97-1 3476
34
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
35
Febuxostat Approved Phase 4 144060-53-7 134018
36
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
37
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
38
Canagliflozin Approved Phase 4 842133-18-0
39
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
40
Amlodipine Approved Phase 4 88150-42-9 2162
41
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
42
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
43
Gliclazide Approved Phase 4 21187-98-4 3475
44
Hydralazine Approved Phase 4 86-54-4 3637
45
Terazosin Approved Phase 4 63590-64-7 5401
46
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
47
Metformin Approved Phase 4 657-24-9 4091 14219
48
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
49
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
50
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130

Interventional clinical trials:

(show top 50) (show all 387)
# Name Status NCT ID Phase Drugs
1 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
2 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
3 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
4 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
5 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
6 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
7 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
8 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
9 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
10 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Unknown status NCT02690883 Phase 4 Exenatide;Lispro
11 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
12 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
13 A Study on the Anti-proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes. Unknown status NCT00749047 Phase 4 Pioglitazone
14 Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
15 Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial Unknown status NCT01500590 Phase 4 Renin-angiotensin system blockers;non-renin angiotensin system blockers
16 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
17 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
18 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
19 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
20 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
21 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
22 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
23 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
24 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
25 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
26 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
27 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
28 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
29 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil;Candesartan Cilexetil 32mg
30 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
31 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
32 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
33 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
34 A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients Completed NCT01664676 Phase 4 Liraglutide;Placebo-liraglutide
35 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH;ACTH
36 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
37 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
38 A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT) Completed NCT00235014 Phase 4 trandolapril;trandolapril/verapamil;placebo;verapamil
39 A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria Completed NCT02829177 Phase 4 Allopurinol;Placebo
40 Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy Completed NCT00276133 Phase 4 Effects of atorvastatin versus probucol on small dense LDL
41 A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese Completed NCT00272831 Phase 4 Cilostazol;Placebo
42 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
43 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
44 The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy Completed NCT01331317 Phase 4 Paricalcitol
45 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial Completed NCT02502071 Phase 4 sodium bicarbonate
46 The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combine Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension Completed NCT00921570 Phase 4 Amlodipine;Valsartan
47 FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients Completed NCT01703234 Phase 4 Ramipril
48 Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose Completed NCT01738945 Phase 4 Amlodipine
49 A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Diabetic Nephropathy With Chronic Kidney Disease Stages III-IV Not on Dialysis, Not Currently Treated With ESA. Completed NCT01191983 Phase 4 Methoxy polyethylene glycol-epoetin beta [Mircera]
50 A Phase 4, Monocenter, Randomized, Double-blind, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Linagliptin Versus the Sulfonylurea (SU) Derivative Glimepiride on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus (T2DM) Completed NCT02106104 Phase 4 Linagliptin 5 mg QD (N=24);Glimepiride 1 mg QD (N=24)

Search NIH Clinical Center for Microvascular Complications of Diabetes 4

Inferred drug relations via UMLS 71 / NDF-RT 50 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Genetic Tests for Microvascular Complications of Diabetes 4

Genetic tests related to Microvascular Complications of Diabetes 4:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 4 29 IL1RN

Anatomical Context for Microvascular Complications of Diabetes 4

MalaCards organs/tissues related to Microvascular Complications of Diabetes 4:

40
Kidney, Endothelial, Pancreas, Heart, Bone, Liver, Monocytes

Publications for Microvascular Complications of Diabetes 4

Articles related to Microvascular Complications of Diabetes 4:

(show top 50) (show all 17603)
# Title Authors PMID Year
1
Polymorphisms in interleukin-1 beta and Interleukin-1 receptor antagonist genes are associated with kidney failure in Korean patients with type 2 diabetes mellitus. 6 56 61
15286433 2004
2
Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. 6 56 61
8786086 1996
3
Interleukin-1 system gene polymorphisms are associated with fat mass in young men. 6
16636119 2006
4
Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1--receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene. 6
10750554 2000
5
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. 6
10746728 2000
6
Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. 6
10025794 1999
7
Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. 6
8500797 1993
8
Diabetic Nephropathy: An Overview. 61
31701441 2020
9
Resveratrol reverts Streptozotocin-induced diabetic nephropathy. 61
31585912 2020
10
Isolating and Culturing Mouse Podocyte Cells to Study Diabetic Nephropathy. 61
31701445 2020
11
Genetic Strategies to Understand Human Diabetic Nephropathy: Wet-Lab Approaches. 61
31701455 2020
12
Modeling Human Diabetic Kidney Disease by Combining Hyperglycemia and Hypertension in a Transgenic Rodent Model. 61
31701444 2020
13
The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats. 61
31585313 2020
14
Tripterygium and its extracts for diabetic nephropathy: Efficacy and pharmacological mechanisms. 61
31707345 2020
15
Methods to Detect Endoplasmic Reticulum Stress and Apoptosis in Diabetic Nephropathy. 61
31701452 2020
16
Genetic Strategies to Understand Human Diabetic Nephropathy: In Silico Strategies for Molecular Data-Association Studies. 61
31701456 2020
17
Assessment of Urinary MicroRNAs by Quantitative Polymerase Chain Reaction in Diabetic Nephropathy Patients. 61
31701457 2020
18
Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy. 61
31701458 2020
19
Non-invasive assessment of early stage diabetic nephropathy by DTI and BOLD MRI. 61
31603347 2020
20
Sex differences in progression of diabetic nephropathy in OVE26 type 1 diabetic mice. 61
31678163 2020
21
Changes in diabetes distress among people with type 2 diabetes during a risk screening programme for diabetic kidney disease - Longitudinal observations of the PRIORITY study. 61
31676252 2020
22
Effect of fosinopril on the renal cortex protein expression profile of Otsuka Long-Evans Tokushima Fatty rats. 61
31853288 2020
23
Examining Cell-Cell Interactions in the Kidney Using AFM Single-Cell Force Spectroscopy. 61
31701454 2020
24
Micro-extraction by packed sorbent combined with UHPLC-ESI-MS/MS for the determination of prostanoids and isoprostanoids in dried blood spots. 61
31514837 2020
25
MicroRNA-544 attenuates diabetic renal injury via suppressing glomerulosclerosis and inflammation by targeting FASN. 61
31323309 2020
26
Evaluation of lipoprotein-associated phospholipase A2 as a marker for renal microvasculopathy in adolescents with Type 1 diabetes. 61
31335994 2020
27
Differential contribution of Nox1, Nox2 and Nox4 to kidney vascular oxidative stress and endothelial dysfunction in obesity. 61
31563085 2020
28
Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury. 61
31097789 2020
29
LNCRNA CDKN2B-AS1 regulates mesangial cell proliferation and extracellular matrix accumulation via miR-424-5p/HMGA2 axis. 61
31707340 2020
30
Oral Magnesium Supplementation Improved Lipid Profile but Increased Insulin Resistance in Patients with Diabetic Nephropathy: a Double-Blind Randomized Controlled Clinical Trial. 61
30835085 2020
31
miR-124a enhances therapeutic effects of bone marrow stromal cells transplant on diabetic nephropathy-related epithelial-to-mesenchymal transition and fibrosis. 61
31190436 2020
32
Pyroptosis: A new frontier in cancer. 61
31710896 2020
33
A Technique for Studying Glomerular Filtration Integrity in the Zebrafish Pronephros. 61
31701443 2020
34
An In Vitro Method to Analyze Glucose Uptake in Podocytes. 61
31701450 2020
35
Formation of Mature Nephrons by Implantation of Human Pluripotent Stem Cell-Derived Progenitors into Mice. 61
31701459 2020
36
Insulin Resistance in Type 1 Diabetes Mellitus and Its Association with Patient's Micro- and Macrovascular Complications, Sex Hormones, and Other Clinical Data. 61
31792784 2019
37
Bioplasmonic paper-based assay for perilipin-2 non-invasively detects renal cancer. 61
31668633 2019
38
BMP-7 inhibits renal fibrosis in diabetic nephropathy via miR-21 downregulation. 61
31655195 2019
39
Fumarate accumulation involved in renal diabetic fibrosis in Goto-Kakizaki rats. 61
31704098 2019
40
Regulatory mechanism of TGF-β1/SGK1 pathway in tubulointerstitial fibrosis of diabetic nephropathy. 61
31841202 2019
41
Angiography and phlebography in a hemodialysis population: A retrospective analysis of interventional results. 61
31303134 2019
42
Modulation of renin angiotensin system components by high glucose levels in the culture of collecting duct cells. 61
31131896 2019
43
Silence of lncRNA GAS5 alleviates high glucose toxicity to human renal tubular epithelial HK-2 cells through regulation of miR-27a. 61
31159592 2019
44
The 2017 Banting Memorial Lecture The diabetic lower limb - a forty year journey: from clinical observation to clinical science. 61
30659650 2019
45
Chronic kidney disease in preeclamptic patients: not found unless searched for-Is a nephrology evaluation useful after an episode of preeclampsia? 61
31317437 2019
46
Tetramethylpyrazine alleviates diabetic nephropathy through the activation of Akt signalling pathway in rats. 61
31682792 2019
47
Metabolomic study of the protective effect of Gandi capsule for diabetic nephropathy. 61
31499054 2019
48
Diabetic Nephropathy Alters the Distribution of Circulating Angiogenic MicroRNAs Among Extracellular Vesicles, HDL, and Ago-2. 61
31506344 2019
49
Inactivation of TSC1 promotes epithelial-mesenchymal transition of renal tubular epithelial cells in mouse diabetic nephropathy. 61
31235817 2019
50
Association of the polymorphisms in FOXO1 gene and diabetic nephropathy risk. 61
30987438 2019

Variations for Microvascular Complications of Diabetes 4

ClinVar genetic disease variations for Microvascular Complications of Diabetes 4:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IL1RN IL1RN, IVS2, 86-BP DUPduplication Pathogenic,risk factor 14674

Expression for Microvascular Complications of Diabetes 4

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 4.

Pathways for Microvascular Complications of Diabetes 4

GO Terms for Microvascular Complications of Diabetes 4

Sources for Microvascular Complications of Diabetes 4

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....